Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on track for VITESSE topline data in Q4 of this year DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the last patient visit has been completed in the Company’s Phase 3 VITESSE clinic ...

股价表现与市场反应 - 公司股价在周二盘后交易中大幅上涨23.65%，收于1.21美元 [1] - 在周二常规交易时段，公司股价下跌51%，收于0.98美元 [1] - 公司股价年初至今下跌96.25% [5] - 公司市值为103万美元，日均交易量为318,090股 [5] 公开发行细节 - 公司定价了一项包销公开发行，目标在扣除费用前筹集约700万美元的总收益 [2] - 此次发行包括251万股普通股以及可购买215万股股票的预先资助权证，发行组合价格为每股1.50美元 [2] - 发行的完成以公司与Decoy Therapeutics Inc的拟议业务合并完成为前提，预计于周三完成 [4] - Ladenburg Thalmann & Co Inc 担任此次发行的唯一账簿管理人 [4] 权证条款与资金用途 - A系列权证和B系列权证的行权价均为每股1.50美元 [3] - B系列权证的行权期为一年，而A系列权证自发行之日起可行权五年 [3] - 权证采用固定定价，无可变定价特征 [3] - 发行所得净收益将用于资助研究项目、偿还Decoy的期票以及满足营运资金需求 [4]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

市场整体表现 - 近期市场出现下跌，多家公司股价经历显著下跌 [1] - 医疗保健板块面临广泛挑战，特别是医疗器械行业公司 [3] - 标普500指数期货在盘前交易中下跌约0.2% [3] Salarius Pharmaceuticals, Inc. (SLRX) - 公司股价大幅下跌约49.5%，至1.01美元 [1][6] - 公司专注于开发癌症治疗方法，过去一年股价在88美元高位和0.91美元低位之间波动 [1] - 公司宣布进行公开发行，拟筹集约700万美元资金，包括超过250万股普通股和额外210万股预融资权证 [1] Vor Biopharma Inc. (VOR) - 公司股价下跌47.77%，至9.82美元 [2][6] - 公司致力于为癌症患者开发工程化造血干细胞疗法，其股价经历了从年度高点65.8美元的重大市场调整 [2] - 公司在肾脏疾病试验取得积极结果后，成功完成了1亿美元的融资，以每股10美元的价格发行了1000万股 [2] Outset Medical, Inc. (OM) - 公司股价下跌46.89%，至6.40美元 [3] - 公司是一家医疗技术公司，开发创新的血液透析系统 [3] Epsium Enterprise Limited (EPSM) - 公司股价下跌43.1%，至3.27美元 [4] - 公司从事酒精饮料进口贸易和批发业务，拥有多元化的葡萄酒和烈酒产品组合，过去一年股价在155美元高位和2.62美元低位之间波动 [4] - 公司针对其股票的异常交易活动发布声明，回应近期的市场行为 [4]

Presentation Ashwani VermaUBS Investment Bank, Research Division All right. Good day, everybody. My name is Ash Verma. I cover SMID cap biotech and spec pharma. And with us, we have PTC Therapeutics, Matt Klein, who is the CEO; and Pierre Gravier, who is the CFO. Guys, thank you for joining us. Matthew KleinCEO & Director Thank you, Ash. Great to be here. Ashwani VermaUBS Investment Bank, Research Division So exciting time in the story with the launch of Sephience. Maybe if you can give a little bit of a ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss, Chief Financial Officer, are scheduled to present and share updates during the Jefferies London Healthcare Conference on Wednesday, November 19, at 6:30 am ET/11:30 am GMT. The link to the live audio webcast of the session is available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/even ...

SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that on November 10, 2025, one new employee was granted an inducement award consisting of a stock option to purchase 4,881 shares of common stock. The option was granted pursuant to the Aardvark Therapeutics, Inc. 2 ...

PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference – London on Tuesday, November 18, at 3:00 p.m. GMT/10:00 a.m. ET. The live and archived fireside chat will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of th ...

Vaxcyte (NasdaqGS:PCVX) FY Conference November 11, 2025 02:30 PM ET Speaker2Okay, good afternoon, everybody. Thanks again for joining us at Guggenheim's second annual Healthcare Innovations Conference here in Boston. Really pleased to be joined by Vaxcyte. I'm Seamus Fernandez, one of Guggenheim's senior biopharma analysts. To my far right is Andrew Guggenheim, President and CFO. To my immediate right, Jim Wassil, EVP and COO of Vaxcyte. You know, always great to see you guys. Maybe Andrew, if you want to j ...

Apogee Therapeutics (NasdaqGM:APGE) FY Conference November 11, 2025 01:30 PM ET Speaker3I'll sign up for it.Speaker0Okay, thanks everybody, and good afternoon to day two of the second annual Guggenheim Healthcare Innovations Conference. I'm Seamus Fernandez, one of the Biopharma team's senior analysts here, and I'm joined by Apogee Therapeutics. We have most of the members of the executive team here. Michael Henderson immediately to my right, CEO, Carl Dambkowski, Chief Medical Officer immediately to Michae ...